Novo (NYSE: NVO), a Denmark-based pharmaceutical leader, has made important breakthroughs over the past decade.
The company initially benefited from its advances, with the stock climbing to an all-time high in 2024.
However, the company has encountered clinical and commercial setbacks since then and has lost substantial market value over the past two years.